This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HealthEquity (HQY) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
HealthEquity (HQY) witnessed strong growth in Service, Custodial and Interchange segments in Q1.
Lilly Begins Coronavirus Study to Evaluate Antibody Therapy
by Zacks Equity Research
Lilly (LLY) initiates dosing in a phase I study to evaluate an antibody candidate for treating COVID-19.
Coronavirus Treatment Search Still on, Lilly, Gilead Give Updates
by Kinjel Shah
Lilly (LLY) begins phase I study on a potential antibody therapy to treat COVID-19. Gilead (GILD) announces mixed results from the second phase III study on remdesivir in patients with moderate COVID-19.
NextGen (NXGN) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
NextGen's (NXGN) fiscal fourth-quarter 2020 results gain from strong Recurring revenues.
3 Strong Pharmaceutical and Biotech Stocks to Buy for Coronavirus Immunity
by Benjamin Rains
Let's dive into three large-cap pharmaceutical and biotech stocks that appear set to grow during the pandemic-induced downturn and the eventual recovery...
Top Stock Picks for Week of June 1, 2020
by Panel Of Zacks Experts
Two Zacks Strong Buy Stocks in Focus.
AbbVie Gets FDA Nod for Oriahnn to Control Menstrual Bleeding
by Zacks Equity Research
The FDA approves AbbVie's (ABBV) Oriahnn oral capsule for checking heavy menstrual bleeding related to uterine fibroids in pre-menopausal women. It will be sold in US markets by June-end.
Lilly's Cyramza Gets FDA Approval for First-Line Lung Cancer
by Zacks Equity Research
FDA approves Lilly's (LLY) Cyramza as a combination regimen for metastatic EGFR-mutated non-small cell lung cancer. Cyramza is now approved for six indications to treat four different types of cancers.
Pfizer's Ibrance Fails in Phase III Early Breast Cancer Study
by Zacks Equity Research
Pfizer's (PFE) phase III PALLAS study compared Ibrance plus standard adjuvant endocrine therapy to standard adjuvant endocrine therapy in HR+, HER2- early breast cancer.
Cooper Companies (COO) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter performance is likely to reflect better-than-expected performance at CVI and CSI.
FDA Okays Lilly's Alzheimer's Disease Diagnostic Agent Tauvid
by Zacks Equity Research
With the US regulatory agency's nod, Eli Lilly's (LLY) Tauvid became the first and the only approved radioactive diagnostic agent to image tau NFTs in the brain for effectively evaluating AD patients.
Pharma Stock Roundup: MRK, RHHBY Give Coronavirus Updates,SNY to Sell Stake in REGN
by Kinjel Shah
Merck (MRK), Glaxo (GSK) and Roche (RHHBY) make progress in coronavirus research efforts.
Veeva Systems (VEEV) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veeva Systems' (VEEV) core Subscription business segment performed impressively in Q1.
3 Investing Facts About Required Minimum Distributions You Need to Know - May 28, 2020
by Zacks Equity Research
Like many investors, you're likely aiming to build a comfortable nest egg to ensure a comfortable retirement. Make sure you know all about what financial planners dub the accumulation and distribution phases of retirement planning.
Sanofi's Dupixent Gets FDA Approval for Eczema in Children
by Zacks.com
Sanofi (SNY) secures an FDA nod for Dupixent as the first biologic medicine for children aged from six to 11 years with moderate-to-severe atopic dermatitis.
Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Zacks.com featured highlights include: Eli Lilly and Company, Quidel, Everbridge and Sprouts Farmers Market
by Zacks Equity Research
Zacks.com featured highlights include: Eli Lilly and Company, Quidel, Everbridge and Sprouts Farmers Market
Top 4 Momentum Anomaly Stocks to Enhance Portfolio Returns
by Zacks Equity Research
These fast movers are currently witnessing a short-term pullback in price. So, this could be a solid entry point for garnering better returns.
Veeva Systems (VEEV) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal first-quarter results are likely to reflect solid show by its segments and robust product portfolio.
Why Is Lilly (LLY) Down 5.5% Since Last Earnings Report?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medtronic (MDT) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks.com
Medtronic (MDT) demonstrates weak fiscal fourth-quarter performances at CER, attributable to dismal show in all major business segments and geographies.
Can Teva (TEVA) Return to Growth in This Year or Next?
by Zacks Equity Research
Though Teva (TEVA) faces several challenges, with encouraging progress on restructuring activities and stabilization in the generics business, it may return to growth in 2020 or 2021.
Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (LLY) Outperforming Other Medical Stocks This Year?
McKesson (MCK) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter 2020 results benefit from strong segmental performance.
J&J to Stop Sale of Talc-Based Baby Powder in North America
by Zacks Equity Research
J&J (JNJ) faces thousands of lawsuits, which claim that its talc-based products, primarily its baby powders, cause cancer.